Lobular neoplasia has been traditionally recognized as a marker of increased risk for subsequent breast carcinoma development; however, molecular studies suggest that it also behaves in a non-obligate precursor manner. We do not know, as yet, how to identify the subgroup of cases that is most likely to progress, but the epidemiological data would indicate that this progression occurs after a long period of time. Thus, the current approach of conservative management of these lesions when identified in excision specimens is justified. Recently, several variants of lobular carcinoma in situ (LCIS), most notably pleomorphic LCIS, have been recognized and these can be difficult to differentiate from ductal carcinoma in situ. Application of strict diagnostic criteria and the judicial use of immunohistochemistry, particularly E-cadherin, can be helpful in this differential diagnosis. Another challenging issue is the management of lobular neoplasia when diagnosed on core biopsy. This controversial issue will be discussed in detail. The goals of this review are (1) to describe the morphological criteria used to diagnose the spectrum of lobular neoplastic lesions, including atypical lobular hyperplasia, LCIS and variants of LCIS; (2) to discuss the data exploring the biological potential of lobular neoplasia from an epidemiological and molecular viewpoint; and (3) to outline the recommendations for management of lobular neoplasia when encountered in core biopsies.
The term 'lobular carcinoma in situ' (LCIS) was first coined by Foote and Stewart 1 over 65 years ago. Their description of the morphological appearance of the disease still holds true today: an entity composed of a monomorphic population of dyshesive cells expanding the terminal duct lobular unit. Almost 40 years after this first description of LCIS, Haagensen et al 2 published their own experience with this disease and concluded that 'lobular neoplasia' was a more appropriate term for this lesion as few cases appeared to progress to invasive carcinoma. With increasing recognition of LCIS, it became apparent that less well-developed forms were more frequently seen in the breast. Page et al used the term atypical lobular hyperplasia (ALH) for these lesions. 3, 4 In practice today, the term lobular neoplasia refers to both ALH and LCIS. Lobular neoplastic lesions have also been classified using an alternative nomenclature: lobular intraepithelial neoplasia, 5 although this classification is used less frequently in clinical practice.
There has been much debate in the literature regarding the natural history of lobular neoplastic lesions. [6] [7] [8] [9] [10] Epidemiological studies have clearly shown lobular neoplasia as a marker of increased risk. [11] [12] [13] [14] However, in recent years, there is increasing evidence that LCIS may also act as a non-obligate precursor in the progression to invasive carcinoma. 7, [15] [16] [17] 
Clinical features
Lobular neoplastic lesions (ALH and LCIS) are often multicentric and bilateral. 1, 18 They occur predominantly in premenopausal women, with most cases being diagnosed in women between 40 and 50 years of age. 13, [19] [20] [21] [22] They are clinically occult, and although they are often also mammographically silent, a significant minority of lobular neoplasia cases diagnosed on core biopsy have associated microcalcifications. [23] [24] [25] [26] Data derived from the Surveillance, Epidemiology and End Results Program 27 have shown that the ageadjusted, age-specific rates of LCIS among women in the United States has increased fourfold between the late 70s (0.9 per 100 000 person years) and late 90s (3.2 per 100 000 person years). Women aged between 50 and 59 years experienced the greatest absolute increase in incidence from 1978 to 1998. This rising incidence was not seen in premenopausal women or in women over 70 years of age. 22 
Epidemiology
Although the morphological distinction between ALH and LCIS is quantitative and based on an arbitrarily set threshold, the epidemiological studies clearly indicate a significantly higher relative risk of subsequent carcinoma development associated with LCIS (eight-to ninefold) compared with ALH (fourto fivefold). 2, 3, 12, 28 The extent of LCIS in the breast does not seem to significantly affect risk. 11, 29, 30 LCIS confers B15% absolute risk of developing breast cancer at 15 years, but a significant number of subsequent carcinomas occur more than 15 years after a diagnosis of LCIS. 2, 12, [19] [20] [21] Although lobular neoplasia has been linked to an increased risk of subsequent carcinoma in either breast, 12, 13, 21 several studies have shown a higher, although not always statistically significant, risk in the ipsilateral breast. 3, 14, 17, 20, 30, 31 Cancer risk in ALH seems to vary with patient age; an initial diagnosis of ALH in postmenopausal women has been associated with a lower risk of subsequent carcinoma development than in premenopausal women. 3, 14, 17, 31 The majority of invasive carcinomas that subsequently occur in cases of lobular neoplasia are ductal, no special type. But invasive lobular carcinomas constitute up to 45% of subsequent carcinomas; 12, 21, 30, 32 this is in sharp contrast to the expected rate (5-14%) of invasive lobular carcinomas in the general population.
Histopathology
Both ALH and LCIS are defined using the criteria of Page and colleagues 3, 33 by a population of cells that are small, round, monomorphic, dyshesive with an increased nuclear to cytoplasmic ratio; ALH is diagnosed when o50% of the acini in the affected terminal duct lobular unit are involved by the lobular proliferation and these cells do not completely occlude the lumen or produce marked distension of the acini (Figure 1) . LCIS is diagnosed when 450% of the acini in the affected terminal duct lobular unit are completely filled and distended by the cellular proliferation ( Figure 2 ). In practice, ALH and LCIS often coexist (Figure 3) , and for this reason, along with the fact that it can be difficult to differentiate ALH from LCIS, some authorities would advocate using the term lobular neoplasia for both lesions. Intracytoplasmic vacuoles are often present in both ALH and LCIS and can be a prominent feature. Pagetoid extension along ducts producing a 'clover leaf' appearance is not uncommon. Although the majority of cells comprising these lobular neoplastic lesions are uniform with 
Variants of LCIS
Several variants of LCIS have been recognized. These include pleomorphic LCIS, pleomorphic apocrine LCIS, LCIS with comedo necrosis and carcinoma in situ with mixed ductal and lobular features. Clear cell and signet ring cell variants of LCIS have also been described.
PLCIS
Pleomorphic LCIS (PLCIS) was first identified as a distinct entity by Eusebi et al 34 in 1992. The few reports that have been published since then have described cases of pleomorphic LCIS associated with invasive lobular carcinoma. [35] [36] [37] Sneige et al 38 described in detail the morphological features of pleomorphic LCIS not associated with invasive lobular carcinoma. The cytological appearances of these cells are quite different to those of classic LCIS. Although the cells appear dyshesive as in classic LCIS, they exhibit a greater degree of nuclear pleomorphism and usually contain abundant cytoplasm ( Figure 5 ). Occasionally, the cytoplasm can appear eosinophilic and finely granular, giving the cells an apocrine appearance (pleomorphic apocrine LCIS) ( Figure 6 ). Central, comedo necrosis and calcifications are quite commonly associated with this lesion and can be confused with comedo ductal carcinoma in situ (DCIS) ( Figure 7 ).
LCIS with Comedo Necrosis
Lobular carcinoma with comedo necrosis 39 has recently been described. Before the widespread use of E-cadherin, such cases were categorized as mixed ductal and lobular carcinoma 30, 40, 41 or carcinoma in situ with indeterminate features. 42 These lesions are comprised of identical cells to those of classic LCIS; namely, small, uniform cells with intracytoplasmic lumina and a dyshesive growth pattern, but in addition, contain central areas of comedo necrosis (Figures 8a and b) . Calcifications are often associated with the areas of necrosis (Figures 8c and d) . One study of 18 cases reported a strong association (67%) with invasive carcinoma. In all, 11 of these invasive carcinomas (92%) were either pure invasive lobular carcinomas or had focal lobular features. 39 
In Situ Carcinoma with Mixed Ductal and Lobular Features
Some in situ lesions show features that resemble both LCIS and DCIS. These cases often are comprised of small, monotonous cells typical of LCIS, but appear more cohesive. Alternatively, these cases may resemble DCIS architecturally with the formation of microacinar-like structures but show dyshesion typical of LCIS ( Figure 9 ). E-cadherin immunohistochemistry may show heterogeneous staining is such cases; in one study, roughly one third of cases were negative for E-cadherin, one third were positive and one third had both positive and negative cells within the same lobular unit. 42 This latter pattern of staining should be differentiated from staining of residual benign epithelial cells in a space filled by lobular neoplastic cells (Figure 10 ).
Immunophenotype
Although both classic lobular neoplasia and the variants of LCIS are almost uniformly positive for hormone receptors (estrogen and progesterone) and negative for E-cadherin, [42] [43] [44] [45] (Figure 8 ) there are important differences in their immunophenotype. Classic LCIS and LCIS with comedo necrosis are negative for HER2 protein overexpression/gene amplification, lack p53 mutations and have a low Ki67 labeling index. Conversely, pleomorphic LCIS may show HER2 protein overexpression/gene amplification (particularly if associated with invasive carcinoma), may show p53 positivity and has a moderate to high Ki67 labeling index. 38, 46 In addition, pleomorphic LCIS is often positive with gross cystic disease fluid protein-15, not surprisingly as these lesions often display apocrine features. High molecular weight cytokeratin positivity has been reported as a useful adjunct in differentiating morphologically ambiguous in situ lesions into ductal or lobular categories. 47 However, others have failed to reproduce these findings. Indeed, positive staining seen with the antibody 34betaE12 in lobular neoplasia may in fact be related to the antigen retrieval process. 48 In addition, although E-cadherin is very useful as an adjunct in differentiating ductal from lobular lesions, morphologically unequivocal cases of LCIS and invasive lobular carcinoma have been shown to demonstrate focal E-cadherin positivity. 49, 50 Dabbs et al 51, 52 recently reported the utility of p120-catenin in both classic and pleomorphic variants of LCIS. Characteristically, this antibody is diffusely localized to the cytoplasm in cases of lobular neoplasia, whereas in ductal lesions it remains localized to the membrane. 
Differential diagnosis
Low-grade DCIS forming a solid growth pattern can be very difficult to differentiate from classic LCIS, even in excisional biopsy specimens. The presence of a dyshesive growth pattern and prominent intracytoplasmic vacuoles favors a diagnosis of lobular neoplasia (Figure 4 ). On the other hand, the presence of microacinar formations in this setting would support a diagnosis of DCIS. (Figure 11 ) E-cadherin immunohistochemistry can be particularly helpful in such cases (Figure 12 ).
Myoepithelial cells may be confused with lobular neoplasia, particular when these cells extend in a pagetoid manner into ducts and show abundant clear cytoplasm. The morphological characteristics of the myoepithelial cell, particularly the small, pyknotic-appearing nucleus and the clear cytoplasm, should help with this differential diagnosis.
Pleomorphic LCIS is very easily confused with high-grade DCIS, particularly when there is associated central necrosis and calcifications. The dyshesive appearance of the cells is helpful in making this diagnosis, as is the lack of E-cadherin staining ( Figure 13) . Lobular neoplasia extending into sclerosing adenosis can be challenging, especially on core biopsies. The use of myoepithelial markers, such as smooth muscle myosin heavy chain or p63, can be very helpful in differentiating this process from an invasive carcinoma.
Molecular studies
Much has been discovered about the molecular genetics of lobular neoplasia in recent years. Most of these studies have focused on in situ lobular lesions associated with adjacent invasive lobular carcinoma. Studies investigating loss of heterozygosity, E-cadherin expression and mutations in the E-cadherin gene, CDH1, have shown a relationship between LCIS and invasive lobular carcinoma. 43, [53] [54] [55] [56] [57] The CDH1 gene is inactivated in both in situ and invasive lobular carcinomas by genetic (inactivating mutations of deletions) or epigenetic (promoter methylation) mechanisms. 43 ,54-58 E-cadherin is a cell adhesion molecule that forms complexes with b-, g-, a-catenins and p120-catenin. Loss of E-cadherin-mediated cell adhesion is believed to account for the dyshesive nature of lobular neoplasia and invasive lobular carcinoma. Invasive lobular carcinomas with adjacent LCIS not only lose E-cadherin, but have also been shown to simultaneously lose b-, g-and a-catenin protein expression. 52 Aberrant cytoplasmic localization of p120-catenin (which may have a role in mediating the oncogenic effects of E-cadherin loss) has also been shown to characterize lobular neoplasia. 52, 58 The development of powerful molecular techniques such as comparative genomic hybridization (CGH) has led to further discoveries in the molecular genetics of lobular neoplasia. 16, 59 Lu et al 59 using conventional chromosomal CGH (cCGH) found alterations at chromosomes 6, 16, 17 and 22. These alterations were found in similar frequency in LCIS and ALH, and therefore, based on these chromosomal CGH profiles, ALH and LCIS were suggested to represent the same genetic stage of development. The alterations found by Lu et al 59 in lobular neoplasia using cCGH were also identified and further refined by a study using array CGH. 16 Altered regions in this study included loss at 16p11.2-p11.1 and loss at 22q11.1. Genes within regions of alteration found in both ALH and LCIS were identified to be involved in the process of luminal morphogenesis. 16, 60 Both ALH and LCIS showed loss of 16q21-q23.1 (E-cadherin gene, CDH1;16q21.1); this region was lost in all matched pairs of LCIS and invasive lobular carcinoma in another study using array CGH. 61 There have been few molecular genetic studies of PLCIS. 46, 62, 63 Although PLCIS shows the characteristic molecular genetic changes of classic lobular neoplasia (gain of 1q and deletion of 16q along with E-cadherin inactivation), this variant of lobular neoplasia also shows HER2/neu amplification, MYC amplification, deletion of 13q and gain of 20q. 46, 62 The molecular data described above suggest that ALH/LCIS behaves in a non-obligate precursor manner. Loss of 16q and gain at 1q in lobular neoplasia points to the possible progression toward a low-grade invasive phenotype, given the frequency of these alterations in low-grade invasive breast cancer. 64 Taken together, however, the molecular genetic and clinicopathological data support lobular neoplasia acting both as a precursor lesion and as a risk indicator for subsequent carcinoma. We cannot, as yet, predict which lobular neoplastic lesions are likely to progress. Further studies are needed to understand and identify the subset of lobular neoplastic lesions that have the highest likelihood of progressing to invasive carcinoma.
Management of lobular neoplasia in core biopsies
The management of lobular neoplasia on core biopsy has received increased attention in the literature over recent years. Over 30 studies have addressed this issue since 1999. [23] [24] [25] Upgrade rates to either DCIS or invasive carcinoma in as many as 40% of cases have been reported, but these studies showed variability in the degree of pathologicalradiological correlation and variations in imaging techniques including the number and caliber of cores taken, and they also included variants of lobular neoplasia. 94, 95 Nevertheless, there is a general consensus that excision should be performed in cases of lobular neoplasia identified on core biopsy when the following conditions apply:
(1) when another lesion that would in itself lead to excision, such as atypical ductal hyperplasia, is also present in the core biopsy; (2) when there is discordance between the radiological and pathological findings; (3) when there is an associated mass lesion or area of architectural distortion; (4) if the lesion shows indeterminate features between a ductal and lobular proliferation; and (5) if the morphology is consistent with pleomorphic LCIS or other variants of LCIS. 81, 96 However, some recent studies have shown that classic lobular neoplasia as the sole lesion identified on core biopsy has been associated with either DCIS or invasive carcinoma in 10-27% of cases. 65, 74, 80, 82, 89 These studies were limited by the small numbers of cases included and by their retrospective nature, which may have lead to selection bias with respect to the patients who underwent immediate excision. More recently, three studies 92, 93, 97 have reported much lower rates of upgrades (1-3%). These studies included relatively large numbers of patients with lobular neoplasia on core biopsy who had immediate excision; larger volumes of tissue were sampled and there was meticulous attention paid to pathological-radiological correlation. The upgrade rates in two of these studies 92, 93 would have been much higher if their cases showing discordant pathological and imaging findings had been included. Of particular note in one of these studies 93 is that, although few of these women with lobular neoplasia on core biopsy had DCIS or invasive carcinoma in the subsequent excision, up to 30% of these women developed DCIS or invasive carcinoma in either the ipsilateral or contralateral breast before or after the core biopsy. Many of the subsequent ipsilateral carcinomas occurred in sites not related to the previous core biopsy.
In summary, the data clearly show that lobular neoplasia can behave both as a high-risk lesion and as a non-obligate precursor. But given the long latency period to progression, conservative management of these lesions when identified in excision specimens remains the mainstay of treatment. We are increasingly recognizing variants of lobular neoplasia, and although their management at present is identical to that of DCIS, it is important to separate these lesions from DCIS so that we can learn more about their biological behavior. Finally, the management of lobular neoplasia when diagnosed on core biopsy remains a controversial issue. But there is general agreement that patients who have a diagnosis of a variant of LCIS on core biopsy should undergo immediate excision. On the other hand, the evidence does not support routine excision following a diagnosis of classic lobular neoplasia on core biopsy when there is complete pathological-mammographic correlation and the suspicious area on imaging has been adequately sampled. Although women with classic lobular neoplasia on core biopsy have a low risk of having a carcinoma at the site of the biopsy, there is an increased risk of developing a subsequent carcinoma in either the ipsilateral or contralateral breast. Thus, these women need close ongoing follow-up.
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